WebApr 10, 2024 · According to the issued ratings of 1 analysts in the last year, the consensus rating for Brainstorm Cell Therapeutics stock is Buy based on the current 1 buy rating for BCLI. The average twelve-month price prediction for Brainstorm Cell Therapeutics is $10.00 with a high price target of $10.00 and a low price target of $10.00. WebApr 4, 2024 · The Brainstorm Cell Therapeutics Inc. stock price gained 2.46% on the last trading day (Thursday, 30th Mar 2024), rising from $2.44 to $2.50. It has now gained 4 …

What Type Of Shareholders Own The Most Number of Brainstorm Cell …

WebTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____] or its assigns (the “Holder”) is entitled, upon the terms and subject to … WebMar 27, 2024 · By Chris Wack. BrainStorm Cell Therapeutics Inc. shares were up 13%, to $1.75, after the company said that the U.S. Food and Drug Administration will hold an … dafecauto

COMMON STOCK PURCHASE WARRANT brainstormcell …

WebMar 29, 2024 · Stock Performance. Shares of Brainstorm Cell were trading at $1.84 as of March 28. Over the last 52-week period, shares are down 41.67%. Given that these returns are generally negative, long-term ... WebApr 13, 2010 · BRAINSTORM CELL THERAPEUTICS, INC. Common Stock Purchase Warrant (Void after April 13, 2024) BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered … WebOct 16, 2024 · TEL AVIV, Oct 16 (Reuters) - BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts ... dafc signature block